Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Lexicon Pharmaceuticals, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Lexicon Pharmaceuticals, Inc. is not a good value stock. Lexicon Pharmaceuticals, Inc. is not a good growth stock. Lexicon Pharmaceuticals, Inc. is not very popular among insiders. Lexicon Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharma...
LXRX Fundamental Data by TradingView

News

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabet
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabet

Globe Newswire Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin TIR measures approach target set by American Diabetes Association Data to be presented...\n more…

HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
HC Wainwright Reiterates "Buy" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Ticker Report Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)s stock had its "buy" rating restated by HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $10.00...\n more…

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Globe Newswire THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences...\n more…

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

Globe Newswire Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration New...\n more…

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by HC Wainwright
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by HC Wainwright

Ticker Report Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on...\n more…

Buy Rating for Lexicon Pharmaceuticals Amid Positive Regulatory and Clinical Developments for ZYNQUISTA
Buy Rating for Lexicon Pharmaceuticals Amid Positive Regulatory and Clinical Developments for ZYNQUISTA

TipRanks Financial Blog H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on August 13. Joseph Pantginis has ...\n more…